Active Biotech AB (publ) New rights issue 2008
Read more >>

Annual General Meeting May 7, 2008
Read more >>

Annual Report 2007
Read the report here >>

Teva Pharmaceutical Industries Ltd has presented results from two pre-clinical studies regarding the laquinimod MS project
April 12-19, 2008 at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago, USA - Read more >>

99th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, USA
April 15, 2008 - "Combining tumor-targeted superantigens with docetaxel results in synergistic anti-tumor effects in B16 tumor bearing mice"

The Ones To Watch - Thomson Scientific's review of phase changes in the pharmaceutical pipeline July-September 2007:
- laquinimod one of the five most promising drugs entering Phase III trials
Read more »

In Swedish (page 70-77) >>

Deloitte EMEA Technology Fast 500 - Active Biotech no 97

Ranking of the region´s fastest growing technology companies according to revenue peformance over the last five years.

Read more >>

Subscribe to reports and press releases from Active Biotech
Fill in form »»

Active Biotech AB, Scheelevägen 22, P.O. Box 724, SE-220 07 Lund, Sweden, Telephone +46 46 19 20 00